LEXX vs. RIGL, PRQR, CNTX, SGMT, CYBN, RAPT, INCR, RZLT, IMAB, and GOSS
Should you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include Rigel Pharmaceuticals (RIGL), ProQR Therapeutics (PRQR), Context Therapeutics (CNTX), Sagimet Biosciences (SGMT), Cybin (CYBN), RAPT Therapeutics (RAPT), InterCure (INCR), Rezolute (RZLT), I-Mab (IMAB), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical preparations" industry.
Rigel Pharmaceuticals (NASDAQ:RIGL) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, community ranking, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.
Lexaria Bioscience has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -16.45%. Lexaria Bioscience's return on equity of 0.00% beat Rigel Pharmaceuticals' return on equity.
Rigel Pharmaceuticals currently has a consensus target price of $5.81, indicating a potential upside of 494.45%. Lexaria Bioscience has a consensus target price of $12.00, indicating a potential upside of 208.48%. Given Lexaria Bioscience's higher probable upside, analysts plainly believe Rigel Pharmaceuticals is more favorable than Lexaria Bioscience.
Rigel Pharmaceuticals has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.99, meaning that its stock price is 1% less volatile than the S&P 500.
In the previous week, Rigel Pharmaceuticals and Rigel Pharmaceuticals both had 2 articles in the media. Rigel Pharmaceuticals' average media sentiment score of 1.59 beat Lexaria Bioscience's score of 0.92 indicating that Lexaria Bioscience is being referred to more favorably in the news media.
66.2% of Rigel Pharmaceuticals shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 9.0% of Rigel Pharmaceuticals shares are held by insiders. Comparatively, 7.6% of Lexaria Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Rigel Pharmaceuticals received 449 more outperform votes than Lexaria Bioscience when rated by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 68.85% of users gave Rigel Pharmaceuticals an outperform vote.
Lexaria Bioscience has lower revenue, but higher earnings than Rigel Pharmaceuticals. Rigel Pharmaceuticals is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.
Summary
Rigel Pharmaceuticals beats Lexaria Bioscience on 10 of the 17 factors compared between the two stocks.
Get Lexaria Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexaria Bioscience Competitors List
Related Companies and Tools
